{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-25-000031","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.648529+00:00","generated_at":"2026-05-22T05:04:49.911319+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"10x Genomics revenue ex-settlement falls 2% YoY; cuts 8% workforce, withdraws FY guidance","bullets":["Q1 revenue $154.9M incl $16.8M patent settlement; ex-settlement $138.1M, down 2% YoY.","Net loss $34.4M vs $59.9M YoY; operating loss $39.3M, improved from $61.5M.","Cutting ~8% of global workforce; expects $5.5-6.5M severance in Q2 2025.","Withdraws full-year 2025 guidance citing US academic/government funding uncertainty.","Q2 2025 revenue guidance $138-142M (ex-settlement), 1% sequential growth at midpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-25-000031","json":"https://secwatch.observer/filing/0001770787-25-000031.json","markdown":"https://secwatch.observer/filing/0001770787-25-000031.md","text":"https://secwatch.observer/filing/0001770787-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078725000031/0001770787-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078725000031/txg-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:04:49.911319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4d1503eed350d602ca5772f2282631eff35d728","claim":"10x Genomics, Inc. announced a restructuring with charges of between $5.5 million and $6.5 million (approximately 8% of the Company’s global workforce).","evidence_excerpt":"On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company’s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5 million and $6.5 million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078725000031/0001770787-25-000031-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"between $5.5 million and $6.5 million"},{"label":"Headcount","value":"approximately 8% of the Company’s global workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}